Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Summary

The purpose of this study is to further figure out differences of glycopyrronium bromide compared to tiotropium in early bronchodilation measured by a comprehensive assessment of lung function that includes hyperinflation and specific airway resistance in patients with moderate to severe COPD.

Timeline

Start

2013-08

Primary completion

2014-01

Completion

2014-01

Outcome

Met primary endpoint

paper Glycopyrronium was superior to tiotropium in terms of early bronchodilation. PMID 27940287 ↗

paper FEV1 AUC0-2h (least squares mean treatment difference = 37 mL; 95% CI: 16, 59 mL; p < 0.01) PMID 27940287 ↗

Publications

• Watz H, Mailander C, May C, Baier M, Kirsten AM. Fast onset of action of glycopyrronium compared with tiotropium in patients with moderate to severe COPD - A randomised, multicentre, crossover trial. Pulm Pharmacol Ther. 2017 Feb;42:13-20. doi: 10.1016/j.pupt.2016.12.001. Epub 2016 Dec 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Glycopyrrolate	Small molecule	44 ug	Inhaled
Subject	Tiotropium	Other / unclassified	18 ug	Inhaled
Background	Salbutamol	Unknown	—	—

Indications